Boothbay Fund Management LLC Buys New Holdings in Shire PLC (SHPG)

Boothbay Fund Management LLC bought a new position in shares of Shire PLC (NASDAQ:SHPG) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 28,325 shares of the biopharmaceutical company’s stock, valued at approximately $4,338,000. Shire makes up approximately 0.7% of Boothbay Fund Management LLC’s investment portfolio, making the stock its 23rd largest holding.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Great West Life Assurance Co. Can grew its position in Shire by 16.7% during the 2nd quarter. Great West Life Assurance Co. Can now owns 58,172 shares of the biopharmaceutical company’s stock worth $9,620,000 after purchasing an additional 8,304 shares in the last quarter. Ingalls & Snyder LLC lifted its position in Shire by 10.8% during the 2nd quarter. Ingalls & Snyder LLC now owns 1,284 shares of the biopharmaceutical company’s stock worth $212,000 after acquiring an additional 125 shares during the last quarter. Pioneer Investment Management Inc. lifted its position in Shire by 331.2% during the 2nd quarter. Pioneer Investment Management Inc. now owns 67,699 shares of the biopharmaceutical company’s stock worth $11,189,000 after acquiring an additional 52,000 shares during the last quarter. Summit Financial Group Inc. acquired a new position in shares of Shire during the second quarter valued at about $275,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Shire by 16.3% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,622 shares of the biopharmaceutical company’s stock valued at $2,086,000 after buying an additional 1,772 shares during the last quarter. 20.28% of the stock is currently owned by institutional investors.

A number of research firms recently weighed in on SHPG. ValuEngine raised shares of Shire from a “hold” rating to a “buy” rating in a research note on Thursday, October 26th. FBR & Co started coverage on shares of Shire in a research note on Thursday, October 19th. They set a “buy” rating and a $201.00 price objective on the stock. Stifel Nicolaus reissued a “buy” rating and set a $245.00 price target on shares of Shire in a research note on Sunday, October 8th. Royal Bank Of Canada restated a “buy” rating and issued a $213.00 price objective on shares of Shire in a report on Monday, October 2nd. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $222.00 price objective on shares of Shire in a report on Thursday, September 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $212.18.

Shire PLC (NASDAQ:SHPG) traded down $1.85 during trading on Thursday, reaching $142.69. 1,072,600 shares of the company were exchanged, compared to its average volume of 1,138,084. The company has a market capitalization of $43,423.72, a P/E ratio of 9.94, a P/E/G ratio of 0.80 and a beta of 1.59. Shire PLC has a 1-year low of $137.17 and a 1-year high of $192.15. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55.

Shire (NASDAQ:SHPG) last released its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating analysts’ consensus estimates of $3.64 by $0.17. The business had revenue of $3.70 billion during the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period last year, the business posted $3.17 EPS. analysts predict that Shire PLC will post 15 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/07/boothbay-fund-management-llc-buys-new-holdings-in-shire-plc-shpg.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit